title: Halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy.
abstract: We present a follow-up case report of a 33-year-old lady with juvenile onset arthritis who developed halo naevi while on treatment with tocilizumab. This case report describes the development of halo naevi, vitiligo and diffuse alopecia areata associated with tocilizumab therapy following infection with Methicillin-resistant Staphylococcus aureus (MRSA) and Panton-Valentine leukocidin positivity. This is the first case that describes these events and supports previous theories on cellular and humoral immunity as causative factors. The regression of melanocytes during treatment with tocilizumab could also implicate IL-6 and sIL-6R as future targets in the treatment of melanoma through its direct effect of melanocytic cytotoxicity, which supports previous studies.
authors: Department of Rheumatology , Chapel Allerton Hospital , Leeds , UK.
authors: Kavitha
authors: K
authors: Nadesalingam
authors: Department of Dermatology , Leeds General Infirmary , Leeds , UK.
authors: Mark
authors: M
authors: Goodfield
authors: University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine , Chapel Allerton Hospital , Leeds , UK.
authors: Paul
authors: P
authors: Emery